{"id":"NCT00843778","sponsor":"UCB Pharma","briefTitle":"Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study","officialTitle":"A Phase IIIB, Multi-center, Open Label Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With DMARDs in Patients With Active Rheumatoid Arthritis Who Participated in C87076.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2009-02-13","resultsPosted":"2013-10-31","lastUpdate":"2014-01-30"},"enrollment":131,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870"]}],"arms":[{"label":"Certolizumab Pegol","type":"EXPERIMENTAL"}],"summary":"To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)","primaryOutcome":{"measure":"Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period","timeFrame":"From Entry Visit up to approximately 144 weeks","effectByArm":[{"arm":"Certolizumab Pegol","deltaMin":70.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":25,"countries":["Austria","France","Germany","Italy","Poland"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":130},"commonTop":["Upper respiratory tract infection","Diarrhoea","Nasopharyngitis","Pharyngitis","Urinary tract infection"]}}